The following is a summary of “Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a ...

ROSE-010 is linked to a greater incidence of nausea, vomiting, and headache than placebo. Conclusion: ROSE-010, a glucagon-like peptide-1 receptor agonist, has been shown to reduce pain in individuals ...

A recent study suggests that GLP-1 receptor agonists (GLP-1RAs) may lower the risk of hematologic cancers, including leukemia ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a ...

Whether you are watching television, scrolling through Instagram, or catching up with an old friend, the topic of weight loss ...

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize ...

An orange a day, regular moderate-to-vigorous exercise, and GLP-1 drugs for diabetes treatment have all been linked to a ...